Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 1031-1036

  Elliot, Emilie ^a,b   Amara, Alieu ^b   Jackson, Akil ^a,b   Moyle, Graeme ^a   Else, Laura ^b   Khoo, Saye ^b   Back, David ^b   Owen, Andrew ^b   Boffito, Marta ^a,c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DOLUTEGRAVIR; ELVITEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; STEADY STATE; TANDEM MASS SPECTROMETRY; DRUG MONITORING; MIDDLE AGED; TIME FACTOR;

ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MIDDLE AGED; QUINOLONES; TIME FACTORS;

EID: 84964402208     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv425     Document Type: Article

References (14)

1. Blanco JL, Whitlock G, Milinkovic A et al. HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opin Pharmacother 2015; 16: 1313-24.
2. Perry CM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribildw): a review of its use in the management of HIV-1 infection in adults. Drugs 2014; 74: 75-97.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
4. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2006.
5. Cohen CJ, Colson AE, Sheble-Hall AG et al. Pilot study of a novel shortcycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials 2007; 8: 19-23.
6. Butler KM. ART with weekends off is noninferior to continuous ART in young people on EFV+2NRTI. In: Abstracts of the 2015 Conference on Retroviruses and Opportunistic Infections (CROI 2015), Seattle, WA, 2015. Oral abstract 38LB. http://www.croiconference.org. International Antiviral Society-USA, San Francisco, CA, USA.
7. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65.
8. Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013; 52: 981-94.
9. Ramanathan S, Mathias AA, German P et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011; 50: 229-44.
10. Brainard DM, Wenning LA, Stone JA et al. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol 2011; 51: 1376-402.
11. Moyle G, Boffito M, Fletcher C et al. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009; 53: 1532-8.
12. Coleman CI, Roberts MS, Sobieraj DM et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012; 28: 669-80.
13. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008; 3: 296-305.
14. Ziagen (abacavir). Summary of Product Characteristics. London: ViiV Healthcare UK Ltd. 2 July 2015.